Article
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer - 1 Sept 2004
Albitar Maher, Do Kim-Anh, Johnson Marcella M, Giles Francis J, Jilani Iman, O'Brien Susan, Cortes Jorge, Thomas Deborah, Rassenti Laura Z, Kipps Thomas J, Kantarjian Hagop M, Keating Michael
Abstract excerpt
BACKGROUND: The CD52 antigen is a glycoprotein anchored on the cell membrane of mature B and T lymphocytes, monocytes, and eosinophils. Alemtuzumab (CAMPATH-1H; anti-CD52) is currently approved for the treatment of patients with refractory chronic lymphocytic leukemia (CLL). The authors investigated the possibility that CD52 may be shed from cells and, once soluble, may bind to injected alemtuzumab, forming...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.